Moreover, this regimen is associated with well-recognized risks—including secondary hyperparathyroidism, nephrocalcinosis, and gastrointestinal intolerance—and does not address the underlying FGF23-mediated disease mechanism [6]. The gene discussed is FGF23; the disease is nephrocalcinosis.